A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

Circulation: Cardiovascular Interventions

Volumn 4, Issue 3, 2011, Pages 266-272

  Read, Philip A ^a,c   Hoole, Stephen P ^a,c   White, Paul A ^b,c   Khan, Fakhar Z ^a,c   O'Sullivan, Michael ^c   West, Nick E J ^c   Dutka, David P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Angioplasty; Glucagon like peptide 1; Myocardial ischemia; Myocardial stunning

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; PLACEBO;

ADULT; AGED; ARTICLE; BALLOON OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; FEMORAL ARTERY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART STROKE VOLUME; HUMAN; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEAN ARTERIAL PRESSURE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BALLOON OCCLUSION; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; PILOT PROJECTS; VENTRICULAR FUNCTION, LEFT;

EID: 84860390563     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.960476     Document Type: Article

References (26)

1. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106-1113. (Pubitemid 43764114)
2. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-151. (Pubitemid 40105106)
3. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005;312:303-308. (Pubitemid 40096482)
4. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437-446.
5. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219-224.
6. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardio-myopathy. Circulation. 2004;110:955-961. (Pubitemid 39128621)
7. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965. (Pubitemid 38282847)
8. Hoole SP, Heck PM, White PA, Read PA, Khan SN, West NE, O'Sullivan M, Dutka DP. Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans insights from simultaneous coronary and left ventricular hemodynamic assessment. J Am Coll Cardiol Cardiovasc Interv. 2010;3:412-418.
9. Porto I, Blackman DJ, Nicolson D, Niccoli G, Kahn FZ, Ormerod O, Forfar C, Channon K, Banning AP. What is the incidence of myocardial necrosis in elective patients discharged on the same day following percutaneous coronary intervention? Heart. 2004;90:1489-1490. (Pubitemid 39626339)
10. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002;39:1738-1744. (Pubitemid 34595282)
11. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522-528. (Pubitemid 36390500)
12. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
13. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, van Dijk AD, Temmerman D, Senden J, Buis B. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation. 1984;70:812-823. (Pubitemid 15205446)
14. Thompson DS, Waldron CB, Juul SM, Naqvi N, Swanton RH, Coltart DJ, Jenkins BS, Webb-Peploe MM. Analysis of left ventricular pressure during isovolumic relaxation in coronary artery disease. Circulation. 1982;65:690-697. (Pubitemid 12133230)
15. Kass DA, Midei M, Brinker J, Maughan WL. Influence of coronary occlusion during PTCA on end-systolic and end-diastolic pressure-volume relations in humans. Circulation. 1990;81:447-460. (Pubitemid 20055952)
16. Bolli R. Mechanism of myocardial "stunning." Circulation. 1990;82: 723-738.
17. Barnes E, Dutka DP, Khan M, Camici PG, Hall RJ. Effect of repeated episodes of reversible myocardial ischemia on myocardial blood flow and function in humans. Am J Physiol Heart Circ Physiol. 2002;282: H1603-H1608. (Pubitemid 34654825)
18. Bolli R, Zughaib M, Li XY, Tang XL, Sun JZ, Triana JF, McCay PB. Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function. A pathophysiological basis for chronic myocardial "stunning." J Clin Invest. 1995;96:1066-1084.
19. Nelson PG. Effect of heparin on serum free-fatty-acids, plasma catechol-amines, and the incidence of arrhythmias following acute myocardial infarction. BMJ. 1970;3:735-737.
20. Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996;78:1350-1354. (Pubitemid 126657226)
21. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med. 2007;356:1140-1151. (Pubitemid 46425598)
22. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588. (Pubitemid 29061876)
23. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008;1:153-160.
24. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12: 694-699. (Pubitemid 44881367)
25. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation. 2008;117:2340-2350. (Pubitemid 351653542)
26. Bahrmann P, Werner GS, Heusch G, Ferrari M, Poerner TC, Voss A, Figulla HR. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation. 2007;115:600-608. (Pubitemid 46226170)